MinervaX is a clinical stage, Danish biotech company developing a novelprotein-only vaccine against Group B Streptococcus (GBS).

This pathogen is the leading cause of life-threatening infections, infection-related deaths and long-term disability in newborns during the first 3 months of life. A vaccine for GBS is highly needed to avoid an estimated 150,.000 preventable stillbirths and infant deaths every year.